Apellis Aims New Pegcetacoplan Data At Market, Not Regulators

 
• By Alaric DeArment
Apellis said it was submitting new, longer-term follow-up data to the FDA for its geographic atrophy drug • Source: Shutterstock

More from Sensory

More from Therapeutic Category